Market Overview

Oculus Receives Mexican Ministry of Health Approval of Microcyn(R)-Based Hydrogel for Management of Scars


Oculus Innovative Sciences (Nasdaq: OCLS) today announced a regulatory approval in Mexico for the company's new Microcyn®-based scar management hydrogel, under the brand name Epicyn™. 

Bruce Thornton, executive vice president of Oculus said: "From a corporate perspective, this is just the first of many opportunities for our new scar management hydrogel formulation outside the United States. In addition to the approval by the Mexican Ministry of Health, our Latin American partner, More Pharma, in parallel with the introduction of the new Epicyn™ Scar Hydrogel in the Mexican dermatology market, intends to move forward to secure regulatory approvals, and subsequent product launches, in additional Latin American countries as well. We are exceedingly proud of our teams in both Mexico and the United States for working in tandem to secure respective regulatory approvals." Oculus announced FDA 510(k) regulatory clearance for the Microcyn® Scar Management HydroGel this past week. 

The medical device approval by the Mexican Ministry of Health is for the care of keloid and hypertrophic scars. In preparation for a commercial launch in the summer of 2014, More Pharma, in concert with

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (OCLS)

View Comments and Join the Discussion!

Benzinga's Top #PreMarket Gainers

PTC Therapeitics Reports Ataluren Clinical Data Demonstrate an Increase in Dystrophin Expression in nmDMD Patients